Systems Biology towards novel chronic kidney disease diagnosis and treatment (SYSKID)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2010
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Chronic Kidney Disease
  • Location: Europe


The Systems Biology towards novel chronic kidney disease diagnosis and treatment (SysKid) consortium is focused on expanding the basic science of chronic kidney disease. The project paves the way for progress in prevention, new diagnostic strategies, and treatment options for declining kidney function, which affects millions of patients suffering from diabetes and hypertension.


The Systems Biology towards novel chronic kidney disease diagnosis and treatment (SysKid) consortium is focused on expanding the basic science of chronic kidney disease. It plans to exploit recent advancements in theoretical as well as experimental concepts and methodologies in systems biology and systems medicine. By integrating high-throughput molecular analysis tools, functional studies in-vitro as well as in-vivo, computational biology models, and simulations, together with clinical and epidemiological data, the consortium aims to study chronic kidney disease (CKD) in the context of diabetes and hypertension.

The major aims of the SysKid consortium:

Aim 1: Identify persons at risk of developing chronic kidney disease utilizing epidemiology as well as molecular tools.

Aim 2: Understand the molecular processes triggering early-stage chronic kidney disease and identify associated biomarkers.

Aim 3: Develop novel diagnostic and therapeutic strategies to control progression of chronic kidney disease.

Aim 4: Perform pre-clinical verification of novel therapy approaches and perform clinical testing of novel diagnostics.

In order to accomplish SysKid’s aims the following subordinate objectives are defined:

Objective 1: Integrate existing and extend clinically well-defined sample cohorts of patients with chronic kidney disease.

Objective 2: Establish and unify a broad ‘omics’ repository characterizing CKD.

Objective 3: Decipher processes, molecular pathways, and associated CKD biomarkers utilizing a systems biology approach.

Objective 4: Use cell cultures and animal models to deepen our understanding of identified processes associated with early CKD.

Objective 5: Delineate novel therapeutic strategies and pre-clinical evaluation for prevention and slowing of progression of chronic renal disease.

Objective 6: Clinical validation of identified biomarkers for generating early-stage diagnosis and prognosis IVD kits.

Objective 7: Delineate a novel risk score for the development of chronic kidney disease.

Objective 8: Deepen our understanding of the epidemiological aspects of early CKD with particular focus on consequences for healthcare policies.


EU FP7, Project reference: 241544, Total cost: EUR 15,743,594



Points of Contact

emergentec biodevelopment GmbH
Gersthofer Strasse 29-31
1180 Vienna, Austria

Sponsors & Partners

Emergentec Biodevelopment GmbH

Medizinische Universitaet Wien

Medizinische Universitaet Innsbruck

Mosaiques Diagnostics GmbH

ProScience Communications

Steno Diabetes Center A/S

Universitaetsklinikum Erlangen

Academisch Ziekenhuis Groningen

Śląski Uniwersytet Medyczny w Katowicach

Semmelweis Egyetem

University of Glasgow

Biocrates Life Sciences AG

Charite-Universitaetsmedizin Berlin


Celera Corporation

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Consiglio Nazionale delle Ricerche

Universite Victor Segalen Bordeaux II

Weizmann Institute of Science

University College Dublin, National University of Ireland, Dublin

Istituto di Richerche Farmacologiche Mario Negri

Universitaet des Saarlandes

Fundacio Privada Institut d’Investigacio Biomedica de Bellvitge

Amgen (Europe) GmbH

Biomarker Design Forschungs GmbH

Universidad de Cordoba

Institut Catala de la Salut

Universitaetsklinikum Aachen

Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.